PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 178 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $5,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $5,000 | +66.7% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $3,000 | -40.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $5,000 | -78.3% | 100 | -66.7% | 0.00% | -85.7% |
| Q4 2015 | $23,000 | +91.7% | 300 | 0.0% | 0.01% | +75.0% |
| Q3 2015 | $12,000 | -7.7% | 300 | +100.0% | 0.00% | +33.3% |
| Q4 2014 | $13,000 | -13.3% | 150 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $15,000 | +66.7% | 150 | +50.0% | 0.00% | +50.0% |
| Q2 2014 | $9,000 | -81.6% | 100 | -85.9% | 0.00% | -80.0% |
| Q1 2014 | $49,000 | +40.0% | 707 | +16.5% | 0.01% | +100.0% |
| Q4 2013 | $35,000 | +20.7% | 607 | 0.0% | 0.01% | +25.0% |
| Q3 2013 | $29,000 | +93.3% | 607 | +19.7% | 0.00% | +100.0% |
| Q2 2013 | $15,000 | – | 507 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |